Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism

Abstract

A positive clinical response to infliximab was associated with a higher CRP level before treatment in our population of Crohn disease patients, but there was no relevant association with -308 TNF gene polymorphism. We therefore suggest that CRP level may help to identify better candidates for infliximab treatment.

The +1059G/C polymorphism in the C‐reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease

“…50 In this context, it is of interest that a response to infliximab was associated with elevated CRP serum concentrations before treatment in CD patients. 51 Similar observations were made in a recent study analysing the efficacy of certolizumab pegol [a polyethylene-glycolated Fab fragment of antitumour necrosis factor (TNF), also named CDP870] 52 and the anti-TNF agent CDP571. 53 Therefore, the knowledge of CRP genotypes influencing CRP levels would be of great value for selecting patients for anti-TNF therapy.…”

Tumor Necrosis Factor-α Allele Lymphotoxin-α+250 Is Associated with the Presence and Severity of Placental Inflammation among Preterm Births

“…The A allele of TNF-␣Ϫ308 occurred more often among children who had Kawasaki disease and developed coronary artery abnormalities (24). Carriage of the A allele of TNF-␣Ϫ308 was associated with worse outcome among patients with cerebral malaria (30), leishmaniasis (31), and severe sepsis (32) but had no effect on the susceptibility to or severity of rheumatoid arthritis (33), multiple sclerosis (34), or Crohn disease (35). Similarly, the A allele of TNF-␣Ϫ238 was associated with severe silicosis (36) but was absent among patients with severe rheumatoid arthritis (33,37).…”

Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study

“…Such a difference in platelet metabolism may thus exist between R and NR to infliximab as illustrated by the significant difference on our H4 spectra. While the elevated CRP level can be used as a predictor of response [22], a high PF4 level determined on spectra could serve as a predictor of non response to infliximab. Although a clinical heterogeneity was visible at baseline between responders and non responders, including factors potentially involved in response to infliximab, such as disease location, CDAI, CRP and steroid use, none of these factors was significantly associated with the PF4 peaks detected by SELDI.…”